Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats

被引:40
作者
de Visser, Yvonne P. [1 ]
Walther, Frans J. [1 ,3 ]
Laghmani, El Houari [1 ]
Steendijk, Paul [2 ]
Middeldorp, Maaike [1 ]
van der Laarse, Arnoud [2 ]
Wagenaar, Gerry T. M. [1 ]
机构
[1] Leiden Univ, Div Neonatol, Dept Pediat, Med Ctr, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Dept Cardiol, Med Ctr, NL-2300 RC Leiden, Netherlands
[3] Harbor Univ Calif, Los Angeles Med Ctr, Los Angeles Biomed Res Inst, Dept Pediat, Torrance, CA USA
基金
美国国家卫生研究院;
关键词
right ventricular hypertrophy; pulmonary hypertension; bronchopulmonary dysplasia; oxidative stress; piclamilast; INDUCED PULMONARY-HYPERTENSION; PROSTACYCLIN ANALOGS; CARDIAC MYOCYTES; EXPRESSION; ALVEOLARISATION; PATHOGENESIS; INFLAMMATION; ROFLUMILAST; OXYGEN;
D O I
10.1152/ajplung.00041.2011
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
de Visser YP, Walther FJ, Laghmani EH, Steendijk P, Middel-dorp M, van der Laarse A, Wagenaar GT. Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats. Am J Physiol Lung Cell Mol Physiol 302: L56-L67, 2012. First published September 23, 2011; doi: 10.1152/ajplung.00041.2011.Phosphodiesterase (PDE) 4 inhibitors are potent anti-inflammatory drugs with antihypertensive properties, and their therapeutic role in bronchopulmonary dysplasia (BPD) is still controversial. We studied the role of PDE4 inhibition with piclamilast on normal lung development and its therapeutic value on pulmonary hypertension (PH) and right ventricular hypertrophy (RVH) in neonatal rats with hyperoxia-induced lung injury, a valuable model for premature infants with severe BPD. The cardiopulmonary effects of piclamilast treatment (5 mg.kg(-1).day(-1)) were investigated in two models of experimental BPD: 1) daily treatment during continuous exposure to hyperoxia for 10 days; and 2) late treatment and injury-recovery in which pups were exposed to hyperoxia or room air for 9 days, followed by 9 or 42 days of recovery in room air combined with treatment started on day 6 of oxygen exposure until day 18. Prophylactic piclamilast treatment reduced pulmonary fibrin deposition, septum thickness, arteriolar wall thickness, arteriolar vascular smooth muscle cell proliferation and RVH, and prolonged survival. In the late treatment and injury-recovery model, hyperoxia caused persistent aberrant alveolar and vascular development, PH, and RVH. Treatment with piclamilast in both models reduced arteriolar wall thickness, attenuated RVH, and improved right ventricular function in the injury recovery model, but did not restore alveolarization or angiogenesis. Treatment with piclamilast did not show adverse cardiopulmonary effects in room air controls in both models. In conclusion, PDE4 inhibition attenuated and partially reversed PH and RVH, but did not advance alveolar development in neonatal rats with hyperoxic lung injury or affect normal lung and heart development.
引用
收藏
页码:L56 / L67
页数:12
相关论文
共 41 条
[1]   Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn [J].
Abman, Steven H. .
NEONATOLOGY, 2007, 91 (04) :283-290
[2]   Impaired Vascular Endothelial Growth Factor Signaling in the Pathogenesis of Neonatal Pulmonary Vascular Disease [J].
Abman, Steven H. .
MEMBRANE RECEPTORS, CHANNELS AND TRANSPORTERS IN PULMONARY CIRCULATION, 2010, 661 :323-335
[3]   Pulmonary hypertension in children: A historical overview Introduction [J].
Abman, Steven H. .
PEDIATRIC CRITICAL CARE MEDICINE, 2010, 11 :S4-S9
[4]   Current concepts: Chronic lung disease after premature birth [J].
Baraldi, Eugenio ;
Filippone, Marco .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (19) :1946-1955
[5]   Microarray analysis of gene expression profiles of cardiac myocytes and fibroblasts after mechanical stress, ionising or ultraviolet radiation [J].
Boerma, M ;
van der Wees, CGC ;
Vrieling, H ;
Svensson, JP ;
Wondergem, J ;
van der Laarse, A ;
Mullenders, LHF ;
van Zeeland, AA .
BMC GENOMICS, 2005, 6 (1)
[6]   Phosphodiesterase inhibitors in airways disease [J].
Chung, KF .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 533 (1-3) :110-117
[7]   Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery [J].
Clapp, LH ;
Finney, P ;
Turcato, S ;
Tran, S ;
Rubin, LJ ;
Tinker, A .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2002, 26 (02) :194-201
[8]   Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling [J].
Conti, M ;
Richter, W ;
Mehats, C ;
Livera, G ;
Park, JY ;
Jin, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (08) :5493-5496
[9]   Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury [J].
Cortijo, J. ;
Iranzo, A. ;
Milara, X. ;
Mata, M. ;
Cerda-Nicolas, M. ;
Ruiz-Saur-, A. ;
Tenor, H. ;
Hatzelmann, A. ;
Morcillo, E. J. .
BRITISH JOURNAL OF PHARMACOLOGY, 2009, 156 (03) :534-544
[10]   Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice [J].
De Franceschi, Lucia ;
Platt, Orah S. ;
Malpeli, Giorgio ;
Janin, Anne ;
Scarpa, Aldo ;
Leboeuf, Christophe ;
Beuzard, Yves ;
Payen, Emmanuel ;
Brugnara, Carlo .
FASEB JOURNAL, 2008, 22 (06) :1849-1860